Comment
Author: Admin | 2025-04-28
Heart disease and stroke. It based its decision on the results from the LEADER trial, which the company that makes Victoza funded.The company states that the trial found that Victoza led to: a 22% reduction in cardiovascular death compared with a placebo a 12% lower risk of non-fatal heart attackan 11% risk reduction of non-fatal strokesTrulicity (dulaglutide)In 2020 the FDA approved Trulicity (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. The FDA based its decision on results from the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. Researchers tested the drug on patients with established CVD and CV risk factor subgroups. The results showed that Trulicity reduced CV events by 12% in the study population. Ozempic and Wegovy (semaglutide)In 2020 The FDA approved Ozempic (semaglutide) for the reduction of stroke, heart attack, and other major adverse cardiovascular events (MACE) in adults with type 2 diabetes and heart disease. The FDA based its decision on outcomes from the 2-year SUSTAIN 6 trial where Ozempic reduced the risk of MACE by 26%. More recently, in 2024, the FDA approved Wegovy (semaglutide) for use in the prevention of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease, with or without type 2 diabetes. The FDA based its decision on results from the SELECT trial. Researchers gave the 17,604 participants a placebo or Wegovy. The results showed that Wegovy reduced the
Add Comment